Want to see NAGE full AI Analyst Report?
NAGE Stock Chart & Stats
$3.27
$0.02(0.62%)
At close: 4:00 PM EDT
$3.27
$0.02(0.62%)
Day’s Range― - ―
52-Week Range$2.61 - $7.95
Previous Close$3.25
Volume413.05K
Average Volume (3M)470.77K
Market Cap
$212.85M
Enterprise Value$198.78M
Total Cash (Recent Filing)$66.74M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)13.9
Beta0.76
Next Earnings
Nov 04, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding79,126,000
10 Day Avg. Volume685,831
30 Day Avg. Volume470,767
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda10.85
Forecast
1Y Price Target
$10.50Price Target Upside221.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.14
Revenue Forecast (FY)$134.14M
Bulls Say, Bears Say
Bulls Say
Profitability And MarginsThe transition from earlier losses to positive operating and net profitability, supported by stable gross margins in the low-to-mid 60% range, indicates a stronger underlying economic model. Maintaining this margin structure would give Niagen capacity to fund product development, marketing, and research while retaining earnings leverage.
Conservative Balance SheetVery low and improving leverage reduces financial risk and gives Niagen flexibility to invest through changing demand conditions without relying heavily on borrowing. A larger equity base and stronger recent returns on equity also provide a more durable foundation for funding growth initiatives and absorbing execution variability.
Scientific And Pharmaceutical ExpansionRegulatory designations and progress on NB4168 broaden Niagen beyond consumer supplements into a potential pharmaceutical pathway. Although development remains ongoing, these steps can strengthen the company’s scientific credibility, expand future applications for NR, and create additional long-term growth avenues.
Bears Say
Weak Revenue MomentumFlat revenue followed by sharply negative latest-TTM growth signals that demand momentum has weakened or normalized after earlier expansion. If this persists, slower scale benefits could limit operating leverage, reduce the resources available for innovation, and make recent profitability more dependent on cost discipline than sustained business growth.
Inconsistent Cash ConversionOperating cash flow below net income indicates that reported earnings are not currently converting into cash as consistently as desired. Combined with earlier cash burn, this creates a continuing execution concern: investment in growth may require careful working-capital management and could constrain the durability of internally funded expansion.
Elevated Development InvestmentThe shift toward telehealth and pharmaceutical development increases the number of initiatives competing for management attention and capital. Because the proposed trial’s size, duration, endpoints, budget, and logistics remain unsettled, spending could rise before these programs produce measurable commercial returns or offset weaker core revenue momentum.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $2.61 and its highest was $7.95 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $212.85M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is Nov 04, 2026 which is in 23 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Aug 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.002.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.01.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 79,126,000 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.01 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went down -14.697%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (221.10% Upside)
$10.50 (221.10% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 67%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 94.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.41%
12-Months-Change
Fundamentals
Return on Equity
20.50%
Trailing 12-Months
Asset Growth
16.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Niagen Bioscience
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
NAGE Company Deck
NAGE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$10.50
▲(221.10% Upside)
Technical Analysis
AC Immune SA
―
Alector
―
Alpha Cognition Inc
―
Telomir Pharmaceuticals, Inc.
―
BioAge Labs, Inc.
―
Ownership Overview
5.07% Insiders
7.91% Mutual Funds
0.03% Other Institutional Investors
78.47% Public Companies and
Individual Investors